Sanofi (SNY) Exercises License Extension Option to Nurix’s (NRIX) STAT6 Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Leerink Partners Reiterates Market Perform Rating on Nurix (NRIX)
June 2, 2025 11:14 AM EDTLeerink Partners analyst Faisal Khurshid reiterated a Market Perform rating and $16.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Bottom Line: This morning NRIX announced that partner SAN FP (OP, Risinger) exercised their option to license NRIX's STAT6 program, including development candidate NX-3911. We believe NRIX's STAT6 program has been seen as an interesting... More
